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Abstract Ras plays the role of a molecular switch in many 
cellular signalling pathways. The Raf-kinase has been identified 
as the direct target molecule of Ras in mammalian eeHs. How- 
ever, in recent reports other proteins have been characterised as 
putative Ras effectors which have neither a functional nor a 
structural relationship to each other. In addition it has been shown 
that also other members of the Ras family like Rap and R-Ras 
can interact with some of these proteins. To address the problem 
of specificity and of biological relevance of the interactions, they 
have to be carefully quantified and the cellular localisation of the 
proteins involved taken into account. 
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proliferation, differentiation and metabolism. Its guanine nu- 
cleotide state is tightly controlled by the two regulatory types 
of molecules Ras-GEF and Ras-GAE Three different GEF 
proteins called Ras-GRF or Cdc25 M, Sos M and C3G and three 
Ras-specific GAPs called pl20-GAP, neurofibromin and 
GaplM have so far been described for mammalian systems (Fig. 
1). These regulators are multifunctional proteins that are poten- 
tially involved in a number of interactions since they contain 
many different modular domains, some of which connect hese 
proteins to events at the plasma membrane or to other small 
GTP-binding proteins such as Rac/Rho. Reviews covering 
these interactions have appeared [4-7]. We will thus confine 
ourselves to the description of the interactions of Ras with its 
downstream effectors. 
1. The functional cycle of GTP-binding proteins 2. Effector Residues of Ras 
GTP-binding proteins function as molecular switches, which 
cycle between the GDP-bound inactive state and the GTP- 
bound active state. Without external activation they are found 
predominantly in the inactive form since GDP is tightly bound 
and the rate of dissociation iscorrespondingly slow. Activation 
occurs when a so-called guanine-nucleotide exchange factor 
GEF accelerates nucleotide release from the protein. Since in 
the cell there is much more GTP than GDP the protein becomes 
predominantly oaded with the guanosine triphosphate and 
thus active. Once activated, GTP-binding proteins can now 
interact with so-called effector molecules and this interaction 
creates ome form of a chemical signal. Effector molecules are 
operationally defined as proteins which interact more strongly 
with the GTP-bound state. Return to the inactive state is due 
to the fact that GTP-binding proteins are also GTPases which 
hydrolyze GTP, albeit slowly, and create inorganic phosphate 
and the GDP-bound state, thus interrupting the signal. The 
GTPase reaction is accelerated by GTPase-Activating Proteins 
(GAPs), which are either purely regulatory proteins or can 
themselves be effectors. General reviews dealing with the gen- 
eral aspects of GTP-binding proteins have appeared [1,2]. 
Ras-related GTP-binding proteins constitute a superfamily 
of proteins with approximately 50-60 members in mammals, 
which based on sequence and functional homology can be 
grouped into the Rac/Rho, Rab/Ypt, Ran, Arf, Rad and the 
actual Ras subfamilies [3]. The Ras family consists of Ras, Rap, 
R-Ras and Ral with various isoforms. Ras itself is a central 
switch in many signal transduction pathways which control 
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Despite an intensive ffort to find it, the effector of Ras has 
been elusive for quite some time. However, it had been shown 
by mutational analysis that residues 32-40 of human Ras and 
similar residues of the yeast Saccharomyces cerevisiae RAS 
were involved in the interaction with effectors ince mutations 
of these residues interrupted the Ras-signalling pathway (sum- 
marized by [8,9]). For example, if mutations such as D38A (and 
many others) are introduced into oncogenic Ras these Ras 
mutants are no longer transforming [10-12]. It was postulated 
that the Ras effector would bind via these residues and that the 
binding was necessary to transmit the signal for transformation 
and proliferation. In support of this concept it was found that 
similar mutations in the RAS gene of the yeast S. cerevisiae 
interrupt he interaction with the yeast RAS effector molecule 
adenylyl cyclase [10]. Since adenylyl cyclase is not the effector 
of mammalian Ras and since mammalian Ras can nevertheless 
complement the loss of the yeast RAS genes, these experiments 
also showed for the first time that there are different effectors 
of Ras and that the interactions between yeast RAS and ade- 
nylyl cyclase and mammalian Ras and its effector are via similar 
structural motifs. 
The structure of the GTP-bound form of Ras showed that 
these residues are located in loop L2 and t-strand 2 and are 
highly exposed to the solvent [13,14]. The structural compari- 
son of the GDP-bound and GTP-bound state also showed that 
there are only two regions of structural difference between the 
active and inactive state, called switch I and II, and that the 
effector egion is one of them (switch I) [14-16]. This was the 
first structural verification of how the conformational change 
is triggered by the loss of the y-phosphate on GTP hydrolysis 
and that these structural changes omehow change the affinity 
towards the effector molecule. 
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Fig. 1. Schematic view of signal transduction from the cell surface to 
the nucleus via the regulatory cycle of the Ras gene product p21. 
Exchange factors catalyse the activation of Ras in transferring it into 
the GTP-bound form. Deactivation by intrinsic GTP hydrolysis of Ras 
can be accelerated by GTPase activating proteins. Only the GTP-bound 
Ras is able to interact strongly with effector molecules which somehow 
transmit the signal to produce a biological readout. 
3. Raf as effector 
The first suggestion that Raf is downstream of Ras came 
from microinjection experiments where it was shown that the 
monoclonal anti-Ras antibody Y 13-259 inhibited the signalling 
via the PDGF receptor, the transforming activity of v-scr and 
v-ras, but not of v-Raf but that an anti-Raf antibody could 
inhibit the transforming activity of v-Ras [17]. Likewise anti- 
sense Raf RNA and dominant negative Raf mutants were 
shown to inhibit ras oncogene mediated signalling [18], and 
many other experiments in different genetic systems implicated 
Raf and Ras in receptor tyrosine kinase (RTK) mediated ef- 
fects. Experiments to prove the direct interaction between Ras 
and Raf by coimmune precipitation with the widely used anti- 
body Y13-259 were unsuccessful due to the fact that Raf and 
Y13-259 interact with the same region on Ras, which is not 
surprising in hindsight since Y13-259 inhibits the biological 
activity of Ras, which again is mediated by Raf. With the use 
of another antibody Y13-238, the arrival of the two-hybrid 
system and the widely used GST-fusion protein constructs, the 
story of Raf as the direct effector protein and the direct proof 
of their interaction was then made independently by several 
laboratories [19-24]. They showed that the regulatory region 
of the c-Raf-1 protein kinase binds tightly to mammalian Ras, 
that this interaction is dependent on GTP and can be inter- 
rupted by mutations in the effector egion, such as D38A, and 
that there is a strong correlation between the biological activity 
of effector mutants and their ability to bind to Raf. 
Vojtek et al. [24] were able to isolate via the two-hybrid 
screen many overlapping fragments of Raf which were able to 
bind to Ras. The only common fragment of these clones con- 
sisted of amino acids 51-131 which have then been shown to 
constitute an independent domain, the Ras-Binding-Domain 
(RBD) [25,26] though other elements of the regulatory region 
of Raf have also been implicated in binding [22,27]. The affinity 
of RBD for p21raS-GTP is in the order of 10-20 nM, and the 
affinity to the GDP-bound form is 1000 fold lower [26]. In vivo 
the binding of Raf kinase to Ras leads to the translocation of 
the kinase to the plasma membrane where Raf gets activated 
by a process that has not been fully elucidated but seems to 
involve the members of the 14-3-3 family of proteins [28]. Raf 
may become fully activated by either autophosphorylation or 
by the action of either Ser/Thr- or Tyr-specific protein kinases 
[29]. The activated Raf kinase is the start of a kinase cascade 
where the next-in-line kinase is activated by phosphorylation 
and then itself activates the next downstream kinase. Raf acti- 
vates MEK which in turn activates ERK which gets translo- 
cated to the nucleus and activates either other kinases uch as 
Rsk or transcription factors such as Elk. The biological role of 
Ras may thus be rather boring, translocating Raf to the plasma 
membrane and presenting it to the activation machinery [30,31], 
an anticlimactic end to a furious search. 
It has been shown that the rate of GTP hydrolysis in the 
Ras-RafRBD complex is the same as that of Ras alone [22,24- 
26] and that GAP is unable to stimulate hydrolysis of Ras in 
the Ras-Raf complex [22,23,25]. Therefore it seems reasonable 
to assume, as proposed before, that the intrinsic GTPase rate 
of Ras is important for signal termination [26,32]. It is possible 
that after activation of Raf, possibly by phosphorylation, Ras 
is released from the complex in order to activate another Raf 
molecule. 
The three-dimensional structure of the RBD domain has 
been determined to be similar to that of ubiquitin structure 
[25,33] and the structure of the complex between Rap lA  in the 
triphosphate form and RBD has also recently been solved by 
X-ray crystallography [34]. Since it involves residues on Rap 1A 
which are identical to Ras, the structure is probably similar to 
that of the corresponding Ras-RafRBD signalling complex. It 
is the first atomic view of the interaction between a GTP- 
binding protein and its effector. It shows that this interaction 
is indeed mediated by the effector esidues of Ras/Rap, part of 
which form an apparent antiparallel fl-sheet with RBD. 
4. Pl(3)kinase 
Since the discovery of Raf as an effector or downstream 
target of Ras, other possible effectors have since been found, 
either by using the two-hybrid system or by measuring the 
direct interaction of isolated proteins. One of them is PI(3)ki- 
nase which consists of two subunits, p85, which contains SH2 
domains involved in receptor interaction, and p 110 which is the 
catalytic subunit. Ras has been shown to bind to both the a and 
fl type p110 subunits [35,36]. The dissociation constant of this 
complex is 500 nM, thus the interaction is weaker than the 
Ras-Raf interaction, but it is again dependent on the presence 
of GTP and effector esidues uch as D38 and is inhibited by 
the Y13-259 antibody. Although it is not quite clear which 
signals are created by this interaction, it apparently leads to a 
modest increase in the PI(3)kinase activity [35,36], thus increas- 
ing the concentration f 3'-phosphorylated inositol ipids which 
are themselves bona fide signal transduction molecules or are 
involved in their generation. Neither the only moderate in- 
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Fig. 2. (A) A schematic presentation f the promiscuity ofthe Ras family members. All direct interactions ofthe members of the Ras subfamily sofar 
reported in the literature (see text) are indicated by arrows. Particularly for Ras and Rap several possibilities for mutual antagonistic a tion by 
competition for the same ffector seem to exist. (B) Sequence alignment ofeffector residues (aa 2045 for K-Ras) of the Ras family proteins. Secondary 
structure lements are given on top. There is an almost complete identity in the core effector region (part of L2 and f12, see hatched bar) which in 
Ras/Rap mediates the interaction with Raf [34]. Ral does not show high homology to the other family members. 
crease in enzymatic activity nor the weak affinity between p2 lraS 
and p110 are necessarily arguments against he biological sig- 
nificance of this interaction, since such types of protein/protein 
interactions may be much more pronounced on a membrane 
surface where both the higher local concentrations in a 'two- 
dimensional solution' and their proper juxtaposition may en- 
hance the biological readout. That PI(3)kinase is not simply a 
downstream target molecule of Ras comes from the observa- 
tion that constitutively active nzyme acts upstream of Ras and 
that its effect is inhibitable by N17Ras [37] and from its role in 
Rac activation [38,39]. 
5. Other candidate effectors 
Recently the case for the existence of further Ras effectors 
was strengthened bythe finding that different effector-site mu- 
tations block different Ras-effector interactions and that two 
such mutations can complement each other in producing a
biological readout [27]. Other proteins have indeed been found 
to bind to Ras in a GTP-dependent manner which, according 
to the definition given, qualifies them as potential Ras effectors 
or targets (Fig. 2A). These are Ral-GEF, the guanine nucleo- 
tide exchange factor for Ral, another protein of the Ras family, 
and molecules that have a high homology to Ral-GEF and have 
been labelled RGL, RalGEF-like [40-42]. These molecules con- 
tain a homologous independently folding domain which is be- 
tween 80 and 100 amino acids long (Herrmann, unpublished). 
The interaction of this domain with Ras in vitro is also medi- 
ated by effector residues, and it may somehow modify the 
enzymatic activity of the RalGEF and thus the nucleotide state 
of Ral. However, since nothing is known about he function of 
Ral, its activation does not help us to explain the function of 
Ras. 
In Saceharomyces pombe, the protein kinase byr2 has been 
defined genetically to be situated ownstream of Ras [43] and 
does in fact bind very tightly with nM affinity to p21 ras in a 
GTP-binding manner [44]. Mammalian homologues of byr2 
termed MEK kinases have been identified, which are serine- 
threonine protein kinases, at least one of which seems to be 
activated in a ras-dependent way, demonstrated bythe inhibi- 
tion through Ras(S 17N) [45]. However, direct binding between 
Ras and MEKK has so far not been demonstrated. An appar- 
ent Ras-dependent MEKK called REKS (for Ras-dependent 
ERK kinase stimulator) has been described biochemically, 
which is immunogenically distinct from Raf, but has not yet 
been cloned molecularly [46]. GTP-dependent binding of Ras 
has also been found for the ( isoform of PKC and this interac- 
tion seems to be stimulated by PDGF in fibroblasts [47]. As 
discussed earlier [4] it is also possible that pl20-GAP, which 
contains many signal transduction modules for protein-protein 
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interactions, may also be a Ras target molecule. It should be 
added that its site of interaction is at least overlapping with the 
effector egion of Ras [8,9]. 
In two recent reports further Ras-binding (Rsb) proteins 
have been identified by using the two-hybrid screen and even 
less is known about these proteins and what effect they might 
have in the biological function of Ras [48]. The human protein 
Rin (Ras interaction/interference) has also been identified as a 
protein that can bind to H-Ras and yeast Ras2 in a manner 
similar to the Ras-Raf interaction, the function of this protein 
being similarly mysterious [49]. Together with the bona-fide 
effectors of Ras in yeast, adenylyl cyclase in S. cerevisiae and 
byr2 in S. pombe, we notice a large number of possible Ras 
effectors, which have at least overlapping binding regions on 
Ras (Fig. 2A). However, so far no sequence similarity has been 
detected between any of these interacting sequences and it will 
be necessary to investigate the structure of these proteins and 
their complexes with Ras to find out whether they have any- 
thing in common with the Ras-Binding Domain of Raf. It will 
also be necessary to find out whether these Ras-effector interac- 
tions feed into different signal transduction pathways. Already 
there is enough evidence to suggest that Ras branches off into 
two different pathways which lead to the activation of Rac and 
MAP kinase, both of which are necessary for cellular transfor- 
mation [39]. 
6. Promiscuity of the Ras-family 
The situation is, however, even more complicated by the 
promiscuity of the Ras family members since it has been shown 
that the other proteins of the Ras subfamily of Ras-related 
GTP-binding proteins, Rapl (A and B) and R-Ras/Tc21, but 
not Ral, also bind to some of the presumed effectors of Ras 
[4042,48,50,51] which is shown schematically in Fig. 2A. The 
reason for this promiscuity seems obvious from the sequence 
alignment of the effector esidues of the Ras family members 
(Fig. 2B). The sequence of the f12 region, which contains many 
of the reported effector residues and mediates the Ras-Raf 
interaction as shown in the 3D structure of the complex [34], 
is identical for most of these proteins. The different subtypes 
of the different effectors uch as three isoforms of Raf and at 
least three isoforms of the RalGEF motif create even more 
possible interactions. 
The task will be to sort out if all of these multiple possible 
interactions are biologically relevant. As a case in point we have 
carefully measured the affinities of different Ras and Ras-like 
proteins with Raf-1 and find that the affinity of Rap 1A is about 
100fold weaker than that of H-Ras. This by itself seems to 
suggest that RaplA is unable to function as a antagonist of the 
Ras signal transduction pathway, as suggested by its ability to 
suppress K-Ras induced transformation and Ras-dependent 
activation of ERK-1 and ERK-2 [52,53]. Measuring the affini- 
ties of these interactions alone may, however, not be sufficient 
to explain biological behaviour. It is becoming increasingly 
evident hat signal transduction pathways depend on the relo- 
calization of proteins away and onto their place of action [54] 
and that protein-protein interactions are modified by the mem- 
brane environment in which they take place. The rate of the 
GTP hydrolysis may be another modulator to be considered. 
In the case of Rap and Ras it has already been found that they 
are located on different membrane compartments and have 
vastly different GTPase rates [55,56]. Thus the question of who 
does it with whom may have to be extended to the question of 
where and for how long in order to sort out the biological 
significance and specificity of effects mediated by Ras and its 
family members. 
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